Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

NCT00423449 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: vorinostat
DRUG: Gemcitabine
DRUG: Platinum-based agent

Sponsor

Merck Sharp & Dohme LLC